Samsung Bioepis Co, Ltd announced that the US Food and Drug Administration (FDA) has approved Ontruzant (trastuzumab─dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible indications
Original Article: Samsung Bioepis oncology biosimilar Ontruzant receives US FDA approval